2401 4TH AVE., SEATTLE, WA
Market cap: $11.5M (2/09/2026)
Price: $6.98
Announces Executive Leadership Transitions to Support Next Phase of Growth
Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality
Aptevo Therapeutics Inc. Approves Reverse Stock Split Amendment
Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025
Reports 3Q25 Financial Results And Provides A Business Update
Material Contracts, Material Modifications to Rights of Security Holders
Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AML
Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules
Q3
Q2
FY 2023
Q1
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(4)
S-1
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Initial Statement of Beneficial Ownership